Protein Kinase C-d in combination therapy with Bortezomib

Bortezomib is a targeted cancer drug which acts by blocking proteasomes, clusters of proteins necessary for tumor cell growth. It induces mitochondrial damage in cancer cells. Dr.Ray Lee and co-researchers have identified PKC-d as the downstream effector molecule which mediates the mitochondrial damage and apoptosis in these cancer cells. This invention has shown that identification of molecular targets in the apoptotic pathway which have ability to directly induce cell death and minimize the development of drug resistance, holds great promise to overcome resistance to conventional chemotherapy. Bortezomib is already in market for treatment of multiple myeloma and promyelocytic leukemia and is widely been studied in combination therapy with other anticancer drugs.

The current invention addresses the exact mechanism of mitochondrial damage and subsequent death of tumor cells by bortezomib by identifying a downstream effector molecule PKC-d.
Global market for apoptosis related products was estimated at US $ 1.5 billion in 2007 with a projected annual growth rate of over 50% over the next 5 years.

Stage of Development
A patent application has been filed with the U.S. Patent and Trademark Office. This technology is part of an active and ongoing research program and has been demonstrated to work in proof-of-concept experiments. It is available for developmental research support/licensing under either exclusive or non-exclusive terms.

Additional Info
� Durrant D et al.(2004) � The bortezomib induced mitochondrial damage is mediated by accumulation of active protein kinase C-d. Biochem Biophys Res Comm 321:905-908.

Type of Offer: Licensing

Next Patent »
« More Healthcare Patents

Share on      

CrowdSell Your Patent